Pharmaceutical industry
Pharmaceutical companies are increasingly turning to the internet to promote their prescription drugs, despite a lack of clear regulatory guidelines from the FDA. Upjohn Co. launched a website for Rogaine (minoxidil) in June, offering customers a list of recommended physicians and a $10-off coupon for a doctor's visit.
Pharmaceutical industry
Belmac Corp. has announced a 26% increase in revenues for the third quarter of 1995, reaching $7,876,000 compared to $6,239,000 in the same period of the prior year. The company's operating performance has also improved, with a reduced net loss of $568,000, or
Drugs
Genelabs Technologies, a diversified international biopharmaceutical and diagnostics company, has announced the completion of the first phase of financing for its Taiwanese joint venture, Genelabs Biotechnology Limited (GBL). The initiative, valued at NT$153 million, marks a significant milestone in the collaboration between Genelabs and the Taiwanese government, aiming to
Drugs
Researchers from the Medical College of Wisconsin, the Good Samaritan Hospital Heart Institute, the University of Southern California, and the Hatter Institute have found that the preventive use of MPL-C immunomodulator significantly reduces cardiac infarct size by more than 50% compared to controls. This discovery was made through preclinical data
Drugs
The US Food and Drug Administration (FDA) has announced the elimination of special restrictions on biotechnology drugs, a move that is expected to save the industry hundreds of millions of dollars and accelerate the development of new treatments. The change in policy comes as the FDA has approved 32 biotech
Drugs
Cambridge NeuroScience, Inc. reported a net loss of $2.8 million for the third quarter ended September 30, 1995, a decrease of 38% from the comparable period in 1994. However, the company made significant progress in the clinical development of CERESTAT(R), a treatment for stroke and traumatic brain injury.
Drugs
Immunex Corporation, a biopharmaceutical company, received an unexpected proposal from American Home Products Corporation to acquire all outstanding shares of Immunex's common stock not held by AHP at $14.50 per share in cash. This move comes after AHP's indirect ownership of 54.6 percent of
Drugs
Researchers at T Cell Sciences, Inc. have reported positive outcomes from the company's first Phase I clinical trial of TP10, a soluble form of complement receptor 1 (sCR1), in patients at risk for Adult Respiratory Distress Syndrome (ARDS). The trial involved 24 patients with acute lung injury arising
Drugs
Sofamor Danek Group, Inc. has signed a letter of intent with Kobayashi Pharmaceutical Co., Ltd. to form a joint venture company, Kobayashi Sofamor Danek, K.K., to market Sofamor Danek's products in Japan. This partnership aims to solidify Sofamor Danek's distribution network in Japan while improving
Drugs
Menorest(R), a transdermal 17-beta estradiol treatment for postmenopausal symptoms, has secured regulatory approval in Italy, Spain, Denmark, Ireland, South Africa, and New Zealand. The patch-based system, developed by Noven Pharmaceuticals, utilizes matrix technology to deliver 17-beta estradiol through the skin and into the bloodstream. With this approval, Menorest(R)
Drugs
Rhone-Poulenc Rorer Inc. (RPR) and Applied Immune Sciences, Inc. (AIS) have entered into a definitive agreement and plan of merger, providing for the acquisition by RPR of AIS at a price of $11.75 per share in cash. The merger agreement contemplates that, following the closing of the tender offer,
Drugs
TheraTech Inc. and Wyeth-Ayerst International Inc., a division of American Home Products Corp., have entered into an agreement to market TheraTech's testosterone transdermal patch in Mexico, Central and South America, non-French-speaking Africa, and the Middle East. The patch is intended for the treatment of male hypogonadism, a condition
